XML 65 R44.htm IDEA: XBRL DOCUMENT v3.22.4

Collaboration Agreements, License Agreement and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail) - AstraZeneca Agreements [Member] $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate against projected net revenues	40.00%
Measurement Input Discount Rate [Member] | Discounted Cash Flow [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Discount rate applied	17.5
U.S./RoW and China [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-contingent upfront payments received	$ 402.2
Variable consideration related to payments for milestones considered probable of being achieved	114.0
Variable consideration related to co-development billings	610.5
Variable consideration related to profit share	$ 7.3

X

- Definition

Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ProceedsFromNonContingentUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Implied royalty rate used to find the net present value of future cash flows.

+ References

No definition available.

+ Details

Name:	fgen_RoyaltyRateOnNetRevenue
Namespace Prefix:	fgen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Variable consideration payment received related to co-development billings.

+ References

No definition available.

+ Details

Name:	fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Variable consideration payment received upon achievement of milestone.

+ References

No definition available.

+ Details

Name:	fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Variable consideration related to profit share.

+ References

No definition available.

+ Details

Name:	fgen_VariableConsiderationRelatedToProfitShare
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Value of input used to measure alternative investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_AlternativeInvestmentMeasurementInput
Namespace Prefix:	us-gaap_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: